Ayala Pharmaceuticals Inc (ADXS)

[Meishairwin]

Investor162, I'm with you. There are are a few people on this board who have what IMHO is a weird and unhealthy fixation on Dan's compensation. Those folks obviously have no experience in venture business or exec comp.

It seems some people are wrapped around their axle about share price when that is simply not what any biotech investor focuses on except as opportunities to trade (if they're of such an inclination). Investors focus on the underlying fundamentals: e.g., Is the company sufficiently capitalized and does the CDO understand the need to raise money at every decent opportunity? Is the company making clinical progress, not only in terms of the science outcomes, but more importantly in the strategic thinking about which trials to initiate with whom and with what designs?

I won't reiterate the extensive accomplishments Dan has managed as CEO -- others have listed them...again and again. But, there are some who are obsessed with the current stock price and how much Dan is being paid. Weird, just weird in my opinion because neither of those issues are things on which you would judge whether a pre-revenue biotech company is going to payoff handsomely for the obvious risk involved.

But, I repeat myself. Sigh.